Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial - Uppaluri, R; Campbell, KM; Egloff, AM (Clin Cancer Res, 2020)